Home - International News - Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value By Syndication Editor Feb 23, 2026 Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value International News 9 Total views No comments Syndication Editor Related Posts AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here? AutoCanada Q1 Earnings Call Highlights Comments (No) Leave a Reply Cancel Reply Save my name, email, and website in this browser for the next time I comment. Hide Comments
Comments (No)